Quantum-Si Incorporated ( (QSI) ) has released its Q3 earnings. Here is a breakdown of the information Quantum-Si Incorporated presented to its investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Quantum-Si Incorporated is a proteomics technology company that specializes in redefining protein analysis through single-molecule detection, aiming to make protein analysis simpler and more informative. In its third quarter 2025 earnings report, Quantum-Si announced a revenue of $552,000 and highlighted successful sequencing on a prototype Proteus system, with its development program remaining on track. The company also emphasized the success of its instrument placement program and the launch of its version 4 Sequencing Kit.
Key financial metrics from the report include a gross profit of $194,000 and a gross margin of 35% for the third quarter. Operating expenses increased to $40.0 million compared to the previous year, while adjusted operating expenses decreased to $21.4 million. The company reported a net loss of $35.7 million for the quarter, with adjusted EBITDA at negative $20.1 million.
Strategically, Quantum-Si is focusing on expanding its customer base through various instrument acquisition options and is on track to launch its version 3 Library Prep Kit by the end of 2025. The company is also preparing for the future launch of its transformative Proteus platform in the second half of 2026.
Looking ahead, Quantum-Si management remains optimistic about increasing awareness and adoption of its technology, and it plans to provide further updates on its development initiatives at the upcoming Investor and Analyst Day on November 19, 2025.